{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T17:27:57Z","timestamp":1791912477600,"version":"4.3.4"},"reference-count":55,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,9,2]],"date-time":"2020-09-02T00:00:00Z","timestamp":1599004800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"DOI":"10.3389\/fneur.2020.00981","type":"journal-article","created":{"date-parts":[[2020,9,2]],"date-time":"2020-09-02T00:23:14Z","timestamp":1599006194000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":41,"title":["From Traditional to Targeted Immunotherapy in Myasthenia Gravis: Prospects for Research"],"prefix":"10.3389","volume":"11","author":[{"given":"Renato","family":"Mantegazza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Antozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,9,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41572-019-0079-y","article-title":"Myasthenia gravis","volume":"5","author":"Gilhus","year":"2019","journal-title":"Nat Rev Dis Primers."},{"key":"B2","doi-asserted-by":"publisher","first-page":"212","DOI":"10.3389\/fimmu.2020.00212","article-title":"Autoantibody specificities in myasthenia gravis; implications for improved diagnostics and therapeutics","volume":"11","author":"Lazaridis","year":"2020","journal-title":"Front Immunol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","article-title":"International consensus guidance for management of myasthenia gravis","volume":"87","author":"Sanders","year":"2016","journal-title":"Neurology."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","article-title":"Myasthenia gravis: subgroup classification and therapeutic strategies","volume":"14","author":"Gilhus","year":"2015","journal-title":"Lancet Neurol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1002\/mus.24769","article-title":"Efficacy of prednisone for treatment of ocular myasthenia (Epitome): a randomized, controlled trial","volume":"53","author":"Benatar","year":"2016","journal-title":"Muscle Nerve."},{"key":"B6","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1212\/01.wnl.0000312374.95186.cc","article-title":"An international, phase III randomized trial of mycophenolate mofetil in myasthenia gravis","volume":"71","author":"Sanders","year":"2008","journal-title":"Neurology"},{"key":"B7","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1002\/mus.24608","article-title":"Two steps forward, one step back: mycophenolate mofetil treatment for myasthenia gravis in the United States","volume":"51","author":"Burns","year":"2015","journal-title":"Muscle Nerve."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1212\/WNL.50.6.1778","article-title":"A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis","volume":"50","author":"Palace","year":"1998","journal-title":"Neurology."},{"key":"B9","doi-asserted-by":"publisher","first-page":"116648","DOI":"10.1016\/j.jns.2019.116648","article-title":"Maintenance immunosuppression in myasthenia gravis, an update","volume":"410","author":"Morren","year":"2020","journal-title":"J Neurol Sci"},{"key":"B10","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1007\/s00415-017-8616-7","article-title":"Efficacy and safety of tacrolimus for myasthenia gravis: a systematic review and meta-analysis","volume":"264","author":"Wang","year":"2017","journal-title":"J Neurol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"CD002275","DOI":"10.1002\/14651858.CD002275","article-title":"Plasma exchange for myasthenia gravis","volume":"4","author":"Gajdos","year":"2002","journal-title":"Cochrane Database Syst Rev."},{"key":"B12","doi-asserted-by":"publisher","first-page":"CD002277","DOI":"10.1002\/14651858.CD002277.pub4","article-title":"Intravenous immunoglobulin for myasthenia gravis","volume":"12","author":"Gajdos","year":"2012","journal-title":"Cochrane Database Syst Rev."},{"key":"B13","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1212\/WNL.0b013e31821e5505","article-title":"Comparison of IVIg and PLEX in patients with myasthenia gravis","volume":"76","author":"Barth","year":"2011","journal-title":"Neurology."},{"key":"B14","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/j.autrev.2013.03.010","article-title":"Etiology of myasthenia gravis: innate immunity signature in pathological thymus","volume":"12","author":"Cavalcante","year":"2013","journal-title":"Autoimmun Rev."},{"key":"B15","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1212\/WNL.55.1.7","article-title":"Practice parameter: thymectomy for autoimmune myasthenia gravis (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology","volume":"55","author":"Gronseth","year":"2000","journal-title":"Neurology."},{"key":"B16","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1056\/NEJMoa1602489","article-title":"Randomized trial of thymectomy in myasthenia gravis","volume":"375","author":"Wolfe","year":"2016","journal-title":"N Engl J Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/S1474-4422(18)30392-2","article-title":"Long-term effect of thymectomy plus prednisone versus prednisone alone in patients with non-thymomatous myasthenia gravis: 2-year extension of the MGTX randomised trial","volume":"18","author":"Wolfe","year":"2019","journal-title":"Lancet Neurol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.thorsurg.2018.12.006","article-title":"Surgical techniques for myasthenia gravis: robotic-assisted thoracoscopic surgery","volume":"29","author":"Feng","year":"2019","journal-title":"Thorac Surg Clin."},{"key":"B19","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1212\/WNL.0000000000004082","article-title":"A propensity score analysis for comparison of T-3b and VATET in myasthenia gravis","volume":"89","author":"Brenna","year":"2017","journal-title":"Neurology"},{"key":"B20","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1212\/WNL.0b013e31827b907b","article-title":"Complete stable remission and autoantibody specificity in myasthenia gravis","volume":"80","author":"Baggi","year":"2013","journal-title":"Neurology."},{"key":"B21","first-page":"255","article-title":"Clinical characteristics of refractory myasthenia gravis patients","volume":"86","author":"Suh","year":"2013","journal-title":"Yale J Biol Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1097\/CND.0000000000000034","article-title":"Treatment-refractory myasthenia gravis","volume":"15","author":"Silvestri","year":"2014","journal-title":"J Clin Neuromuscul Dis."},{"key":"B23","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1002\/mus.26507","article-title":"Refractory myasthenia gravis: characteristics of a portuguese cohort","volume":"60","author":"Santos","year":"2019","journal-title":"Muscle Nerve."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/1756285617749134","article-title":"When myasthenia gravis is deemed refractory: clinical signposts and treatment strategies","volume":"11","author":"Mantegazza","year":"2018","journal-title":"Ther Adv Neurol Disord."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/1756286419832242","article-title":"Understanding the burden of refractory myasthenia gravis","volume":"12","author":"Schneider-Gold","year":"2019","journal-title":"Ther Adv Neurol Disord."},{"key":"B26","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1007\/s00415-016-8072-9","article-title":"Validation of the MG-DIS: a disability assessment for myasthenia gravis","volume":"263","author":"Raggi","year":"2016","journal-title":"J Neurol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"e1425","DOI":"10.1212\/WNL.0000000000005323","article-title":"Randomized study of adjunctive Belimumab in participants with generalized myasthenia gravis","volume":"90","author":"Hewett","year":"2018","journal-title":"Neurology."},{"key":"B28","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1097\/00005072-198003000-00005","article-title":"Ultrastructural localization of the terminal and lytic ninth complement component (C9) at the motor end-plate in myasthenia gravis","volume":"36","author":"Sahashi","year":"1980","journal-title":"J Neuropathol Experimental Neurol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","article-title":"REGAIN Study Group. Safety and efficacy of Eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study","volume":"16","author":"Howard","year":"2017","journal-title":"Lancet Neurol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1002\/mus.26447","article-title":"Regain Study Group. Long-term safety and efficacy of eculizumab in generalized myasthenia gravis","volume":"60","author":"Muppidi","year":"2019","journal-title":"Muscle Nerve"},{"key":"B31","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1056\/NEJMoa1900866","article-title":"Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder","volume":"381","author":"Pittock","year":"2019","journal-title":"N Engl J Med."},{"key":"B32","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1111\/bjh.12347","article-title":"Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria","volume":"162","author":"Hillmen","year":"2013","journal-title":"Br J Haematol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1001\/jamaneurol.2019.5125","article-title":"Clinical effects of the self-administered subcutaneous complement inhibitor zilucoplan in patients with moderate to severe generalized myasthenia gravis. Results of a phase 2 randomized, double-blind, placebo-controlled multicenter clinical trial","volume":"77","author":"Howard","year":"2020","journal-title":"JAMA Neurol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"e0195909","DOI":"10.1371\/journal.pone.0195909","article-title":"Design and preclinical characterization of ALXN1210: a novel anti-C5 antibody with extended duration of action","volume":"13","author":"Sheridan","year":"2018","journal-title":"PLoS ONE."},{"key":"B35","doi-asserted-by":"publisher","first-page":"102366","DOI":"10.1016\/j.autrev.2019.102366","article-title":"Next-generation Fc receptor-targeting biologics for autoimmune diseases","volume":"18","author":"Zuercher","year":"2019","journal-title":"Autoimm Rev."},{"key":"B36","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1038\/nri2155","article-title":"FcRn: the neonatal Fc receptor comes of age","volume":"7","author":"Roopenian","year":"2007","journal-title":"Nat Rev Immunol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"4372","DOI":"10.1172\/JCI97911","article-title":"Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans","volume":"128","author":"Ulrichts","year":"2018","journal-title":"J Clin Invest."},{"key":"B38","doi-asserted-by":"publisher","first-page":"e2661","DOI":"10.1212\/WNL.0000000000007600","article-title":"Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis","volume":"92","author":"Howard","year":"2019","journal-title":"Neurology."},{"key":"B39","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s40265-019-1065-0","article-title":"Therapies directed against B-cells and downstream effectors in generalized autoimmune myasthenia gravis: current status","volume":"79","author":"Beecher","year":"2019","journal-title":"Drugs."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1212\/WNL.0000000000004341","article-title":"Rituximab as treatment for anti-MuSK myasthenia gravis: multicenter blinded prospective review","volume":"89","author":"Hehir","year":"2017","journal-title":"Neurology"},{"key":"B41","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1002\/acn3.564","article-title":"The impact of rituximab infusion protocol on the long-term outcome in anti-MuSK myasthenia gravis","volume":"5","author":"Cort\u00e9s-Vicente","year":"2018","journal-title":"Ann Clin Transl Neurol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1002\/mus.25597","article-title":"Rituximab treatment of myasthenia gravis: a systematic review","volume":"56","author":"Tandan","year":"2017","journal-title":"Muscle Nerve."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1001\/jamaneurol.2020.0851","article-title":"Rituximab treatment for new-onset generalized myasthenia gravis and refractory generalized myasthenia gravis","volume":"4","author":"Brauner","year":"2020","journal-title":"JAMA Neurol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1186\/cc11304","article-title":"Clinical review: serious adverse events associated with the use of rituximab - a critical care","volume":"16","author":"Kasi","year":"2012","journal-title":"Critical Care."},{"key":"B45","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1097\/BOR.0000000000000647","article-title":"Diagnosis and treatment of myasthenia gravis","volume":"31","author":"Mantegazza","year":"2019","journal-title":"Curr Opin Rheumatol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"240","DOI":"10.3389\/fimmu.2020.00240","article-title":"New approaches to targeting B cells for myasthenia gravis therapy","volume":"11","author":"Huda","year":"2020","journal-title":"Front Immunol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s40263-020-00704-w","article-title":"Anti-CD20 monoclonal antibodies for relapsing and progressive multiple sclerosis","volume":"34","author":"Sellebjerg","year":"2020","journal-title":"CNS Drugs."},{"key":"B48","doi-asserted-by":"publisher","first-page":"2895","DOI":"10.1111\/ajt.14872","article-title":"Characterization of the in vitro and in vivo properties of CFZ533, a blocking and non-depleting anti-CD40 monoclonal antibody","volume":"18","author":"Ristov","year":"2018","journal-title":"Am J Transplant."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.4049\/jimmunol.1301555","article-title":"Proteasome inhibition with bortezomib depletes plasma cells and specific autoantibody production in primary thymic cell cultures from early-onset myasthenia gravis patients","volume":"193","author":"Gomez","year":"2014","journal-title":"J Immunol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.4049\/jimmunol.1002539","article-title":"Proteasome inhibition with bortezomib depletes plasma cells and autoantibodies in experimental autoimmune myasthenia gravis","volume":"186","author":"Gomez","year":"2011","journal-title":"J Immunol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.jneuroim.2008.05.010","article-title":"Serum BAFF expression in patients with myasthenia gravis","volume":"199","author":"Kim","year":"2008","journal-title":"J Neuroimmunol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"104315","DOI":"10.1016\/j.neuint.2018.10.012","article-title":"Blockade of IL-6 signaling in neuromyelitis optica","volume":"130","author":"Araki","year":"2019","journal-title":"Neurochem Int."},{"key":"B53","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.jaut.2010.12.001","article-title":"Blocking of IL-6 suppresses experimental autoimmune myasthenia gravis","volume":"36","author":"Aricha","year":"2011","journal-title":"J Autoimmun."},{"key":"B54","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.nmd.2017.03.007","article-title":"Beneficial effect of tocilizumab in myasthenia gravis refractory to rituximab","volume":"27","author":"Jonsson","year":"2017","journal-title":"Neuromuscular Disord."},{"key":"B55","doi-asserted-by":"publisher","first-page":"142","DOI":"10.3389\/fimmu.2020.00142","article-title":"miR-146a in myasthenia gravis thymus bridges innate immunity with autoimmunity and is linked to therapeutic effects of corticosteroids","volume":"11","author":"Bortone","year":"2020","journal-title":"Front Immunol."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fneur.2020.00981\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,2]],"date-time":"2020-09-02T00:23:16Z","timestamp":1599006196000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fneur.2020.00981\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,2]]},"references-count":55,"alternative-id":["10.3389\/fneur.2020.00981"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2020.00981","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,2]]},"article-number":"981"}}